Navigation Links
Sentien Biotechnologies Announces Open IND in Phase 1/2 Trial of SBI-101 for Patients with COVID-19
Date:8/21/2020

Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application for the evaluation of Sentien’s lead asset, SBI-101, for the treatment of severe COVID-19. Approval of this IND allows Sentien to initiate a Phase 1/2 study with a focus on COVID-19 patients suffering from both acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI) requiring renal replacement therapy (RRT).

SBI-101 is a combination product that integrates allogeneic mesenchymal stromal cells (MSCs) within an extracorporeal, blood-filtration device. MSCs are a unique source of therapeutic secreted factors that modulate the immune-mediated inflammatory response to acute organ injury. By keeping the MSCs confined within a blood-filtration device, SBI-101 enables controlled, dynamic, and sustained delivery of MSC-secreted factors to the patient’s blood, without the need for direct injection of the MSCs themselves. SBI-101 integrates into a standard blood circuit such as used with renal replacement therapy, thereby providing patients with both standard-of-care and MSC-mediated blood conditioning in a single session.

“There is a compelling scientific rationale for studying SBI-101’s effect on COVID-19. SBI-101 is designed to restore balance to a dysregulated immune system; we believe this design is well suited to calm the hyperinflammatory cytokine storm associated with severe COVID-19 patients,” said Sentien Chief Medical Officer, Allen R. Nissenson, MD.

“COVID-19 is a very logical application for SBI-101,” said Sentien CEO, Brian Miller. “Our previous study of SBI-101 in subjects with dialysis-requiring AKI showed preliminary evidence of anti-inflammatory effects consistent with the SBI-101 therapeutic hypothesis. We are fortunate to have been well-positioned to now focus our attention on COVID-19 patients, who obviously have an urgent need for therapeutics.”

“We are excited to have clearance from FDA to initiate this study of SBI-101 in the COVID-19 patient population,” said Sentien Executive Chairman, Richard Ganz. “Sentien’s mission has always been to develop cell therapies to address diseases characterized by systemic inflammation. The emergence of COVID-19 has served to strengthen our mission even more.”

The multi-center trial is a randomized, controlled, ascending dose Phase 1/2 study in patients with COVID-19 requiring RRT. The primary objective of the trial is to evaluate the safety and tolerability of SBI-101; endpoints for efficacy and pharmacodynamic responses to SBI-101 therapy will also be evaluated.

Please visit https://clinicaltrials.gov/ct2/show/NCT04445220 for more information about the study.

About Sentien Biotechnologies

Sentien Biotechnologies, Inc. is a privately-held, clinical-stage company developing novel ex-vivo cell therapy applications to treat conditions caused by systemic, immune-mediated inflammation. Sentien’s lead product, SBI-101, integrates allogeneic mesenchymal stromal cells (MSCs) within an extracorporeal, hollow-fiber device. By immobilizing MSCs within a blood-filtration device, SBI-101 enables controlled, dynamic, and sustained delivery of MSC-secreted factors to the patient’s blood, without the need for direct injection of the MSCs themselves.

SBI-101 has been evaluated in a Phase 1b/2a study in subjects with dialysis-requiring acute kidney injury (AKI-D). An initial readout from the study provides preliminary evidence of anti-inflammatory and wound healing effects consistent with the SBI-101 therapeutic hypothesis. Building on this data, SBI-101 is being investigated in COVID-19 patients suffering from severe systemic inflammation.

Sentien’s technology can be applied to additional systemic inflammatory indications in both acute and chronic diseases, focusing on complex conditions where single-factor agents have not been effective.

For more information, please visit http://www.sentienbiotech.com.

Read the full story at https://www.prweb.com/releases/sentien_biotechnologies_announces_open_ind_in_phase_1_2_trial_of_sbi_101_for_patients_with_covid_19/prweb17329526.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology news :

1. Lifecycle Biotechnologies Introduces High Purity Powder Chemicals Capabilities
2. Lifecycle Biotechnologies Releases 2020 Company Prospectus
3. Lifecycle Biotechnologies Completes Full Integration of Chata Biosystems and VI Plastics
4. Lifecycle Biotechnologies launches second generation CHEM+POUR Bag
5. Lifecycle Biotechnologies Announces Cellular Agriculture Expansion
6. Jessica Wein Joins Lifecycle Biotechnologies As Marketing Strategist
7. Lifecycle Biotechnologies Announces Promotion of Cindy Baptiste to Business Development Manager
8. Lifecycle Biotechnologies Releases Company Catalog
9. Lifecycle Biotechnologies Launches 100-Liter SAFEthread Drum
10. William Muzek joins Lifecycle Biotechnologies as Business Development Manager
11. Evonik Industries Selects OPX Biotechnologies for Joint Development of Bio-Based Chemicals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology: